Research Projects

MYCOMBIO. Use of MYC inhibition to overcome immunotherapy resistance in KRAS-driven NSCLC with diverse mutational profiles.

Dr. Silvestre Vicent Cambra Curriculum

Researcher | Principal Investigator Oncogenes and Effector Targets Research Group

Research program

Solid Tumors

Research group

Oncogenes and Effector Targets

Project information

The main objective of MYCOMBIO, a Líneas Estratégicas project presented by Peptomyc in collaboration with VHIO (Dr. Soucek), Hospital Universitario 12 de Octubre (HU12O; Dr. Zugazagoitia) and Cima Universidad de Navarra (CIMA; Dr. Vicent), is to determine the therapeutic effect of a first-in-class MYC inhibitor, OMO-103, in KRAS-driven lung tumors with different mutational profiles and to define MYC’s role in reprogramming the tumor/host immune system crosstalk in these different contexts.

In addition, it will assess potential synergies between OMO-103 and current immunotherapies to overcome, or potentially prevent, the development of immunotherapeutic resistance.

Reference: PLEC2021-007959/MCIN/AEI /10.13039/501100011033 y por la Unión Europea NextGenerationEU/ PRTR
Start date: December 1, 2021
End date: November 30, 2024
Funder: Ministerio de Ciencia e Innovación
Grant: 268.098€
Nature of project: National
Award year 2021

Need more information?

If you are interested in learning more about our research, please contact us.